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a b s t r a c t
Background: Routine administration of all age-appropriate doses of vaccines during the same visit is recommended for children by the National Vaccine Advisory Committee (NVAC) and the Advisory Committee
on Immunization Practices (ACIP).
Methods: Evaluate the potentially achievable vaccination coverage for ≥4 doses of diphtheria and tetanus
toxoids and acellular pertussis vaccine (4+DTaP), ≥4 doses of pneumococcal conjugate vaccine (4+PCV),
and the full series of Haemophilus inﬂuenzae type b vaccine (Hib-FS) with simultaneous administration
of all recommended childhood vaccines. Compare the potentially achievable vaccination coverage to the
reported vaccination coverage for calendar years 2001 through 2013; by state in the United States and by
selected socio-demographic factors in 2013. The potentially achievable vaccination coverage was deﬁned
as the coverage possible for the recommended 4+DTaP, 4+PCV, and Hib-FS if missed opportunities for
simultaneous administration of all age-appropriate doses of vaccines for children had been eliminated.
Results: Compared to the reported vaccination coverage, the potentially achievable vaccination coverage
for 4+DTaP, 4+PCV, and Hib-FS could have increased signiﬁcantly (P < 0.001), the vaccination coverage
would have achieved the 90% target of Healthy People 2020 for the three vaccines beginning in 2005, 2008,
and 2011 respectively. In 2013, the potentially achievable vaccination coverage increased signiﬁcantly
across all selected socio-demographic factors, potentially achievable vaccination coverage would have
reached the 90% target for more than 51% of the states in the United States.
Conclusions: The ﬁndings in this study suggest that fully utilization of all opportunities for simultaneous administration of all age-eligible childhood doses of vaccines during the same vaccination visit
is a critical strategy for achieving the vaccination coverage target of Healthy People 2020. Encouraging
providers to deliver all recommended vaccines that are due at each visit by implementing client reminder
and recall systems might decrease missed opportunities for simultaneous administration of childhood
vaccines.
Published by Elsevier Ltd.

1. Introduction
Routine administration of all age-appropriate doses of childhood vaccines during the same health care provider visit is the
standard for childhood immunization practices and has been
approved and recommended by the National Vaccine Advisory

夽 Disclaimer: The ﬁndings and conclusions in this article are solely the responsibility of the authors and do not necessarily represent the ofﬁcial view of Centers for
Disease Control and Prevention.
∗ Corresponding author. Tel.: +1 404 639 8238; fax: +1 404 639 3266.
E-mail address: zaz0@cdc.gov (Z. Zhao).
http://dx.doi.org/10.1016/j.vaccine.2016.04.097
0264-410X/Published by Elsevier Ltd.
This document is a U.S. government work and
is not subject to copyright in the United States.

Committee (NVAC), the Advisory Committee on Immunization
Practices (ACIP), the American Academy of Pediatrics (AAP), and the
American Academy of Family Physicians (AAFP) [1]. Simultaneous
administration of childhood vaccines is deﬁned as administering
more than one recommended vaccine on the same visit day, at
different anatomic sites, and not combined in the same syringe
[2]. Simultaneous administration of all vaccines for which a child
is eligible is an important strategy for ensuring that vaccinations
are received on schedule, and for bringing children who have
fallen behind on their vaccines up to date [3]. It is also an important standard crucial to increasing immunization rate, achieving
and maintaining the national target of vaccination coverage level
among children of 19–35 months for all recommended vaccines
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[1–5]. Experimental evidence and extensive clinical experience
show that giving all age-appropriate childhood vaccines simultaneously is a safe and efﬁcacious practice [2,3,6]. Data from
vaccination coverage surveys have indicated that failing to administer all vaccines for which a child is eligible is an important cause
of low vaccination coverage [3]. Surveys of vaccination records
from 21 selected cities and localities in the United States have
shown that each child had many opportunities for the simultaneous administration of vaccines that, if used appropriately, could
have potentially raised vaccination coverage levels by 12–22 percentage points with median of 17 percentage points [7]. A recent
study from Nebraska has reported that 77% of children who were
behind on their vaccinations at 24 months could have been up to
date if appropriate vaccines had been given simultaneously [8].
A study from immunization record audits in the State of Georgia
has demonstrated that vaccination coverage increased signiﬁcantly
when missed opportunities to administer vaccines simultaneously
were reduced [9]. Missed opportunities for simultaneous vaccinations were recognized as one of the two main causes for children
falling behind in their vaccination [10].
The studies cited above indicate that simultaneous administration of age-appropriate childhood vaccine could have increased
children’s vaccination coverage rates signiﬁcantly, but those results
were limited to the selected states and local areas and did not evaluate the vaccination coverage that could be potentially achieved
at the national level. Since 1995, the Centers for Disease Control
and Prevention (CDC) has been estimating and reporting national,
state, and selected local area vaccination coverage among children 19–35 months in the United States [11]. Those reports point
out that vaccination coverage levels for most of the routine childhood vaccines have reached the Healthy People 2020 target of
90% [4]. However, vaccination coverage for ≥4 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (4+DTaP),
≥4 doses of pneumococcal conjugate vaccine (4+PCV), and the full
series of Haemophilus inﬂuenzae type b vaccine (Hib-FS) have not
yet reached the 90% target. Therefore, in this current study, we
applied the important immunization practice standard, i.e. simultaneous administration of childhood vaccines at the same visit, to the
National Immunization Survey (NIS), the largest vaccination survey in the United States. We evaluated the potentially achievable
vaccination coverage for 4+DTaP, 4+PCV, and Hib-FS for calendar
years 2001 through 2013 in the United States; by 50 U.S. states and
DC, and by selected socio-demographic factors in 2013. All potentially achievable vaccination coverage levels were compared to the
corresponding reported vaccination coverage levels to assess the
impact of simultaneous administration of childhood vaccines on
vaccination coverage.

2. Methods
2.1. Data sources
National Immunization Survey (NIS) data collected from 2001
through 2013 were analyzed in this study. The NIS is conducted
annually by the Centers for Disease Control and Prevention (CDC)
to obtain national, state, and selected local area estimates of vaccination coverage for the U.S. non-institutionalized population of
children 19–35 months [11]. The NIS is a random-digit-dialed telephone survey of households with age eligible children followed
by a mail survey to children’s immunization providers to obtain
provider-reported vaccination histories. Smith et al. [12] provide
a detailed description of the complex survey design used by the
NIS, which has been approved by CDC Institutional Review Board.
Detailed descriptions of the 2001–2013 NIS and corresponding
response rates have been published elsewhere [13–16].
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2.2. Selected socio-demographic factors
The following socio-demographic factors available in the NIS
related to the child, mother, family, and vaccination provider which
have previously been found to be associated with childhood vaccination coverage in the United States were evaluated in this study,
including child’s ﬁrst born status (yes vs. no), number of children
in the family (1 vs. ≥2), family poverty level (at/above vs. below
poverty), family locality (urban, suburban, rural), mobility status
since birth (not moved vs. moved), education level of mother (≤12
years vs. ≥13 years), marital status of mother (married vs. not married), age group of mother (≤29 years vs. ≥30 years), and number
(1 vs. ≥2) and type (public, other, private) of child’s vaccination
providers. Children were deﬁned as having health insurance if they
were covered through the parents’ employer or union or by Medicaid, S-CHIP, the Indian Health Service, Military Health Care, Tricare,
Champus, Champ-VA, other health insurance, or another health
care plan.
2.3. Outcome measures and deﬁnitions
Vaccines are recommended by ACIP for children during the ﬁrst
2 years of life to protect them against 14 vaccine-preventable diseases and include: varicella, Haemophilus inﬂuenzae type b (Hib),
measles, mumps, and rubella (MMR), rotavirus (RV), pneumococcal
conjugate vaccine (PCV), diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus (IPV), hepatitis A (HepA),
hepatitis B (HepB), and inﬂuenza vaccines [4,17]. As reported by
CDC, the vaccination coverage for 3+DTaP, 3+PCV, and the primary
series of Haemophilus inﬂuenzae type b (Hib-PS) have reached the
90% target for years, but for 4+DTaP, 4+PCV, and the full series of
Haemophilus inﬂuenzae type b (Hib-FS), the vaccination coverage
have not achieved the 90% target yet [11]. Therefore we must focus
on the last dose of vaccines in those 3 vaccination series. A missed
opportunity was deﬁned as the failure to administer the fourth dose
of DTaP, the fourth dose of PCV, and the booster dose of Hib vaccine
for the full series of Hib (Hib-FS), and during the same age eligible
period, for the 3 vaccines just mentioned, when a child received one
or more other needed and age appropriate vaccines [7]. Potentially
achievable vaccination coverage was deﬁned as the maximum coverage possible for the recommended 4+DTaP, 4+PCV, and Hib-FS if
missed opportunities deﬁned above had been eliminated [7].
The primary series of Haemophilus inﬂuenzae type b (Hib-PS)
includes ≥2 or ≥3 doses of Hib vaccine depending on product type.
The full series of Haemophilus inﬂuenzae type b (Hib-FS) includes ≥3
or ≥4 doses of Hib vaccine depending on product type received (i.e.
includes the primary series plus the booster dose). In this current
study, data analyses for Hib were limited to 2011–2013 because
a shortage of Hib vaccine occurred in the United States during
December 2007–September 2009 which resulted in an interim recommendation to defer the booster dose of Hib for Hib-FS; children
included in the 2009 and 2010 NIS samples were affected by the
temporary recommendation to suspend the booster dose of Hib for
Hib-FS vaccine [13].
Because the pneumococcal conjugate vaccine shortages during
2001–2004 in the United States, the CDC recommended that all
health care providers temporarily suspend routine administration
of the fourth doses of PCV, thus children included in the 2001–2004
samples were affected by the deferring of the fourth dose of PCV
[18]. Therefore the data from NIS 2005 to 2013 were included and
analyzed for the PCV vaccination study.
2.4. Statistical analyses
All of the analyses in this study were performed using SAS
callable SUDAAN 11.0.0 [19], which properly accounts for the
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Fig. 1. Potentially achievable vs. reported vaccination coverage and 95% conﬁdence interval for 4+DTaP*, 4+HPV† , Hib-FS§ , National Immunization Survey, United States,
2001–2013. *≥4 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. † ≥4 doses of pneumococcal conjugate vaccine (PCV). § Full series Haemophilus
inﬂuenzae type b (Hib) vaccine: ≥3 or ≥4 doses of Haemophilus inﬂuenzae type b (Hib-FS) vaccine depending on product type received (includes primary series plus the booster
dose). Footnote for (B): Because of the pneumococcal conjugate vaccine shortages during 2001–2004 in the United States, children included in the 2001–2004 samples were
affected by the deferring of the fourth dose of PCV, therefore the data from NIS 2005–2013 were included for the PCV vaccination study. Footnote for (C): Hib data were
limited to 2011–2013 because a shortage of Hib vaccine occurred in the United States during December 2007 to September 2009, children were affected by the temporary
recommendation to suspend the booster dose of Hib for Hib-FS vaccine.

complex sampling survey design in the NIS. The potentially achievable and reported vaccination coverage, and the 95% conﬁdence
interval (CI) were estimated with weighted categorical data analyses procedures; t-tests were applied to compare the potentially
achievable vaccination coverage with the reported vaccination coverage. The NIS methodology has been approved annually by the
Ethics and Research Review Board of the National Center for Health
Statistics since it was initiated in 1994.
3. Results
3.1. Potentially achievable
vs. reported vaccination coverage for 4+DTaP, 4+PCV, and the full
series of Hib (Hib-FS), 2001–2013
If the recommended standards of childhood immunization practices for simultaneous administration of the fourth dose of DTaP
vaccine had been implemented fully according to the general ACIP
recommended vaccination schedule, compared to the reported

vaccination coverage for 4+DTaP, the potentially achievable vaccination coverage for 4+DTaP would have increased signiﬁcantly each
year from 2001 through 2013 (P < 0.001) (Fig. 1(A)). The increases
of vaccination coverage ranged from 3.9 percentage points to 7.2
percentage points with median of 6.7 percentage points. During
2001–2013, the potentially achievable vaccination coverage for
4+DTaP would have reached or been very close to the 90% target.
Speciﬁcally beginning in 2005, the potentially achievable vaccination coverage for 4+DTaP would have reached or surpassed the 90%
target speciﬁed by Healthy People 2020.
If missed opportunities for simultaneous administration of the
fourth dose of PCV had been eliminated, the potentially achievable
vaccination coverage for 4+PCV would be signiﬁcantly higher than
the reported vaccination coverage (P < 0.001) (Fig. 1(B)). Beginning
in 2008, the potentially achievable vaccination coverage for 4+PCV
would have reached and been signiﬁcantly higher than the 90% target (P < 0.05). Simultaneous administration could have signiﬁcantly
increased the coverage for 4+PCV by 8.1 percentage points to 31.1
percentage points with median increase of 12.2 percentage points.
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Table 1
Potentially achievable vs. reported vaccination coverage and 95% conﬁdence interval for 4+DTaP* , 4+PCV† , and the Full Series Hib§ , by selected socio-demographic factors,
National Immunization Survey, United States, 2013.
Factors

4+DTaP

US National

4+PCV

Full Series Hib

Potentially achievable
%(95%CI¶ )

Reported
%(95%CI)

Potentially achievable
%(95%CI)

Reported
%(95%CI)

Potentially achievable
%(95%CI)

90.1 ± 1.1**

83.1 ± 1.3

91.3 ± 1.0**

82.0 ± 1.3

92.2 ± 0.9**

82.0 ± 1.3

Reported
%(95%CI)

Health insurance of
child

No
Yes

86.8 ± 2.2
90.9 ± 1.2**

77.0 ± 3.0
84.5 ± 1.4

86.9 ± 2.3
92.3 ± 1.1**

74.8 ± 2.8
83.7 ± 1.5

89.1 ± 2.1
92.9 ± 1.1**

75.9 ± 3.0
83.5 ± 1.5

Family poverty level

Below
At/above

87.4 ± 2.3
91.6 ± 1.1**

77.8 ± 2.7
86.0 ± 1.3

87.5 ± 2.3
93.1 ± 0.9**

74.5 ± 2.7
86.1 ± 1.4

89.0 ± 2.2
93.8 ± 0.9**

75.8 ± 2.8
85.3 ± 1.4

First born child

No
Yes

88.5 ± 1.5
92.7 ± 1.4**

80.2 ± 1.8
87.5 ± 1.7

90.2 ± 1.4**
92.9 ± 1.3**

79.3 ± 1.8
86.1 ± 1.8

91.0 ± 1.3**
94.0 ± 1.2**

79.0 ± 1.8
86.6 ± 1.7

Number of children in
family

1
≥2

92.4 ± 1.8**
89.3 ± 1.3

86.6 ± 2.1
81.7 ± 1.6

92.7 ± 1.7**
90.7 ± 1.2**

85.7 ± 2.2
80.5 ± 1.6

93.7 ± 1.6**
91.6 ± 1.2**

86.2 ± 2.2
80.3 ± 1.6

Family locality

Urban
Suburban
Rural

91.8 ± 3.5**
93.1 ± 2.9**
92.8 ± 3.3**

84.2 ± 4.2
83.8 ± 4.2
85.9 ± 4.4

92.5 ± 2.9**
92.0 ± 3.3**
90.1 ± 4.0**

84.8 ± 4.1
84.2 ± 3.9
77.7 ± 5.6

95.2 ± 2.2**
93.2 ± 2.9**
92.2 ± 3.7**

85.7 ± 3.7
82.9 ± 4.3
79.3 ± 5.5

Family mobility

Moved
Not moved

86.2 ± 3.5
90.6 ± 1.1**

75.5 ± 4.7
83.9 ± 1.3

85.2 ± 3.6
91.9 ± 1.0**

71.7 ± 4.4
83.1 ± 1.4

87.1 ± 3.1
92.8 ± 1.0**

72.3 ± 4.8
83.1 ± 1.4

Education level of
mother

≤12 years
≥13 years

87.6 ± 2.0
92.2 ± 1.1**

79.3 ± 2.3
86.1 ± 1.3

88.8 ± 1.9
93.2 ± 1.0**

76.5 ± 2.4
86.4 ± 1.4

90.4 ± 1.7**
93.6 ± 1.0**

77.8 ± 2.4
85.4 ± 1.4

Marital status of
mother

Married
Not married

91.7 ± 1.1**
87.6 ± 2.1

85.5 ± 1.4
79.0 ± 2.5

92.7 ± 1.0**
88.9 ± 2.0

84.5 ± 1.5
77.9 ± 2.5

93.9 ± 0.9**
89.4 ± 2.0

84.0 ± 1.5
78.7 ± 2.5

Age group of mother

≤29 years
≥30 years

87.0 ± 1.9
92.7 ± 1.2**

78.1 ± 2.3
87.1 ± 1.4

89.1 ± 1.7
93.0 ± 1.1**

77.8 ± 2.3
85.4 ± 1.6

90.1 ± 1.7**
93.9 ± 1.1**

77.8 ± 2.3
85.5 ± 1.5

Number of vaccination
providers

1
≥2

91.0 ± 1.3**
88.5 ± 1.9

84.0 ± 1.5
81.4 ± 2.3

92.3 ± 1.2**
89.3 ± 1.9

83.5 ± 1.6
79.2 ± 2.4

93.3 ± 1.1**
90.2 ± 1.8**

83.3 ± 1.6
79.5 ± 2.3

Type of vaccination
providers

Public
Other
Private

90.2 ± 2.4**
88.7 ± 1.9
92.0 ± 1.5**

80.1 ± 3.8
82.4 ± 2.1
85.2 ± 1.7

87.4 ± 3.0
89.8 ± 1.7
94.1 ± 1.3**

74.6 ± 4.0
81.3 ± 2.2
85.1 ± 1.8

89.9 ± 2.5
90.1 ± 1.8**
95.0 ± 1.2**

76.1 ± 4.4
80.9 ± 2.2
85.0 ± 1.7

≥4 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine.
≥4 doses of pneumococcal conjugate vaccine (PCV).
§
Full series Haemophilus inﬂuenzae type b (Hib) vaccine: ≥3 or ≥4 doses of Haemophilus inﬂuenzae type b (Hib-FS) vaccine depending on product type received (includes
primary series plus the booster dose).
¶
95% Conﬁdence Interval.
**
Potentially achievable vaccination coverage would have reached the 90% target.
*

†

If all opportunities for simultaneous administration of the
booster dose of Hib vaccine for Hib-FS had been taken, compared
to the reported vaccination coverage for the full series of Hib, the
potentially achievable vaccination coverage for the Hib-FS would
have increased 10.2 percentage points to 12.6 percentage points
with median increase of 10.9 percentage points (Fig. 1(C)). The
potentially achievable vaccination coverage for the full series of Hib
would have been signiﬁcantly higher than the reported vaccination
coverage (P < 0.001). The potentially achievable vaccination coverage for the Hib-FS would have reached the 90% target beginning in
2011.
3.2. Potentially achievable vs. reported vaccination coverage by
selected socio-demographic factors in 2013
Potentially achievable vaccination coverage was compared to
the reported vaccination coverage for 4+DTaP, 4+PCV, and the full
series of Hib by selected socio-demographic factors (Table 1). If all
opportunities for simultaneous administration of the fourth dose
of DTaP, the fourth dose of PCV, and the booster dose of Hib vaccine for the full series of Hib (Hib-FS) had been used, compared to
the reported vaccination coverage, the potentially achievable vaccination coverage would have increased signiﬁcantly across each
of the eleven selected socio-demographic factors for the three vaccine series at levels of P < 0.05, P < 0.01, and P < 0.01 respectively.
The potentially achievable vaccination coverage for 4+DTaP would
have increased by 5.2 percentage points to 10.7 percentage points

(median 7.1 percentage points), for 4+PCV by 6.8 percentage points
to 13.5 percentage points (median 8.9 percentage points), for the
full series of Hib by 7.4 percentage points to 14.8 percentage points
(median 10.1 percentage points) across each of the eleven sociodemographic factors. The reported vaccination coverage for 4+DTaP
was signiﬁcantly lower than the Healthy People 2020 target of
90% at level of P < 0.01 over all selected socio-demographic factors except rural area, for which the difference was not signiﬁcant
at level of P < 0.05. The reported vaccination coverages for 4+PCV
and the full series of Hib were signiﬁcantly lower than the Healthy
People 2020 target of 90% at level of P < 0.05 across all selected
socio-demographic factors. However, the potentially achievable
vaccination coverage would have reached the 90% target for 14,
15, and 19 categories out of the total 24 categories from the 11
factors by 4+DTaP, 4+PCV, and the full series of Hib respectively as
presented in Table 1.
3.3. Potentially achievable vs. reported vaccination coverage by
state in the United States in 2013
If the fourth dose of DTaP had been administered simultaneously
at all opportunities available, compared to the reported vaccination coverage, the potentially achievable vaccination coverage for
4+DTaP could have increased in 49 states and DC by 2.2 percentage
points to 12.7 percentage points (median 7.1 percentage points)
(Fig. 2(A)). The only exception is Nevada for which an increase of
0.51% was observed. Moreover, for 19 states and DC, the potentially
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Fig. 2. Potentially achievable vs. reported vaccination coverage and 95% conﬁdence interval for the 4+DTaP*, 4+PCV† , Hib-FS§ , by State in the United States, National
Immunization Survey, 2013. * ≥4 doses of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. † ≥4 doses of pneumococcal conjugate vaccine (PCV). § Full
series Haemophilus inﬂuenzae type b (Hib) vaccine: ≥3 or ≥4 doses of Haemophilus inﬂuenzae type b (Hib-FS) vaccine depending on product type received (includes primary
series plus the booster dose).

achievable vaccination coverage would have increased signiﬁcantly
at level of P < 0.05. On the reported vaccination coverage for 4+DTaP,
only ﬁve states reached the 90% vaccination coverage target; however, for the potentially achievable vaccination coverage, 27 states
and DC would have reached 90% target in 2013.
If all opportunities for simultaneous administration of the fourth
dose of PCV had been used appropriately, compared to the reported
vaccination coverage, the potentially achievable vaccination coverage for 4+PCV would have increased across all 50 states and DC by
2.5 percentage points to 17.8 percentage points (median 8.8 percentage points) (Fig. 2(B)). In addition, for 32 states and DC the
potentially achievable vaccination coverage would have increased
signiﬁcantly at level of P < 0.05. On the reported vaccination coverage for 4+PCV, only six states achieved the 90% target; however, for
the potentially achievable vaccination coverage, 35 states and DC
would have reached the 90% target in 2013.
Had the recommendation for simultaneous administration of
the booster dose of Hib for Hib-FS been in effect and adhered to,
compared to the reported vaccination coverage, the potentially

achievable vaccination coverage for the full series of Hib would
have increased across all 50 states and DC (Fig. 2(C)) by 3.6 percentage points to 16.1 percentage points (median 9.4 percentage
points). Also, for 42 states and DC the potentially achievable vaccination coverage would have increased signiﬁcantly at level of
P < 0.05. On the reported coverage for full series of Hib, only two
states reached the 90% target; however, for the potentially achievable vaccination coverage, 39 states and DC would have reached
the 90% target in 2013.

4. Discussion
Immunization recommendations in the United States currently
target 14 vaccine-preventable diseases for children [4,17], it is
very important to achieve the national immunization targets for
children outlined in the Healthy People 2020, a nationwide health
promotion and disease prevention agenda from the US Department of Health and Human Services. Achieving these objectives
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will improve the health and welfare of all children as well as the
communities in which they live [4]. However, the regular calendar year estimates of vaccination coverage based on NIS indicate
that the reported vaccination coverage for 4+DTaP, 4+PCV, and
the full series of Hib for the U.S national and the majority of the
states in the United States have been well below the 90% target
level for years [11]. In order to increase vaccination coverage levels, one of the Immunization Strategies for Healthcare Practices
and Providers is to reduce missed opportunities for simultaneous
administration of childhood vaccines [5]. This current study applied
that strategy to NIS data and demonstrated that if missed opportunities for simultaneous administration of childhood vaccines had
been eliminated, compared to the reported vaccination coverage,
the potentially achievable vaccination coverage for 4+DTaP, 4+PCV,
and the full series of Hib would have increased signiﬁcantly, and
could have achieved the 90% target in the United States. Rapid
rise in reported vaccination coverage for 4+PCV between 2005 and
2008 likely reﬂects relative newness of PCV vaccine to the schedule
(2000) and, in part, PCV shortages between 2001 and 2004.
An increasing proportion of children vaccination visits include
simultaneous administration of childhood vaccines. Future introduction of new vaccines to protect against multiple diseases will
further increase the number of injections at routine childhood vaccination visits. Parental and healthcare provider attitudes toward
simultaneous administration of childhood vaccines may affect
acceptance of recommended vaccines. An article [20] conducted
a systematic review of the literature to examine factors underlying reported parental and healthcare provider concerns and
practices related to simultaneous administration of childhood vaccines during the same vaccination visits. That study indicated that
providers and parents report concerns about multiple vaccination,
which tend to increase with increasing numbers of vaccination.
Common parental and provider concerns included apprehension
about the pain experienced by the child, worry about potential side effects, and uncertainty about vaccine effectiveness. That
study pointed out that multiple studies reported that a positive
provider recommendation to the parent and a high level of concern
about the severity of the target disease were signiﬁcantly associated with parental acceptance of simultaneous administration
of childhood vaccines. Providers often signiﬁcantly overestimated
parental concerns about simultaneous vaccination, and their overestimation of parental concerns may lead them to postpone
recommended vaccinations, which may result in extra visits and
delayed vaccination. More research is needed on interventions
to overcome provider and parental concern about simultaneous
vaccination.
This study has some limitations that must be acknowledged.
First, we assumed all visits for which we had data were eligible
for vaccination. Because DTaP vaccination requires a minimum of
6 months interval between the third and fourth dose, we may
have overestimated the frequency of missed opportunities for
the fourth dose of DTaP and therefore overestimated the potentially achievable vaccination coverage for 4+DTaP. Second, we only
evaluated healthcare visits when a vaccination was administered,
however, there are other healthcare visits where missed opportunities may occur, such as acute care visits or follow-up visits.
Therefore, in this current study, the assessment of the impact on
vaccination coverage levels by eliminating missed opportunities
for simultaneous administration of childhood vaccines is conservative [7]. Furthermore, if all of the other missed visit opportunities
for childhood immunization could have been eliminated, then
higher potentially achievable vaccination coverage levels might
be attained. Finally, the annual surveys of the NIS from 2001
through 2010 used in this study collected data from households
with a landline-phones, while the 2011 to 2013 surveys collected
data from households with both landlines and cell-phones service.
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However, recent studies [21,22] indicated that the survey nonresponse and non-coverage bias in estimates of vaccination coverage
might be quite small, the total survey error followed a normal distribution with mean of 1.72 percentage points (95% CI: 1.71–1.74
percentage points) and ﬁnal adjusted survey weights corrected for
this error. Although small, the largest contributor to the total survey error in terms of magnitude was nonresponse of immunization
providers.
Strategies designed to prevent missed opportunities have taken
many different forms, used alone or in combination. Standing
orders is the ﬁrst. These are protocols whereby non-physician
immunization personnel may vaccinate clients without direct
physician involvement at the time of the immunization. Standing orders are implemented in settings such as clinics, hospitals,
and nursing homes. When used alone or in combination with
other interventions, standing orders have had positive effects on
immunization rates among children. Provider education is the
second strategy. Anyone responsible for administering immunizations should be knowledgeable about principles of vaccination and
vaccination scheduling, to the extent required for their position.
Providers are largely responsible for educating their patients, so an
investment in provider education will result in a higher level of
understanding about immunizations among the public in general.
Numerous educational materials, in a variety of formats, are available from CDC, the Immunization Action Coalition, and some state
health departments, hospitals, or professional organizations. Incorporating some AFIX principles (i.e., assessment, feedback) into a
provider education program might have a greater effect on provider
behavior than an education effort aimed only at increasing knowledge. The last strategy is the Provider reminder and recall systems
which use client reminder and recall interventions to remind parents that vaccinations are due (reminders) or late (recall), while
effective in increasing immunization levels, can also help avoid
missed opportunities if they are a component of other practices
directed toward this goal. For example, if a reminder system is used
consistently and staff members are knowledgeable about vaccination opportunities and valid contraindications, the system can be
an additional aid in promoting appropriate immunization practices
[5,23].
5. Conclusions
The ﬁndings in this study suggest that fully utilization of all
opportunities for simultaneous administration of all age-eligible
childhood doses of vaccines during the same vaccination visit is
a critical strategy for achieving the vaccination coverage target
of Healthy People 2020. If simultaneous administration of all
age-appropriate doses of vaccines had been fully carried out
according to the general ACIP recommended vaccination schedule,
potentially achievable vaccination coverage for 4+DTaP, 4+PCV,
and Hib-FS could have reached the 90% target of Healthy People
2020 at the levels of national, states, and socio-demographic
factors in the United States. Encouraging providers to deliver all
recommended vaccines that are due at each visit by implementing
client reminder and recall systems might decrease missed opportunities for simultaneous administration of childhood vaccines.
Conﬂict of interest statement: No conﬂicts of interest.
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